AHA/ACC-defined stage 1 hypertensive adults do not display cutaneous microvascular endothelial dysfunction

Gabrielle A Dillon1, Jody L Greaney1,2, Sean Shank1

  • 1Noll Laboratory, Department of Kinesiology, The Pennsylvania State University, University Park, Pennsylvania.

Insights

Stage 1 hypertension (HTN1) does not show impaired nitric oxide-mediated dilation, unlike stage 2 hypertension (HTN2). However, reduced endothelium-dependent dilation occurs in adults with hypertension who do not experience a nighttime blood pressure dip.

Area of Science:

  • Cardiovascular Science
  • Hypertension Research
  • Endothelial Function Studies

Background:

  • The 2017 AHA/ACC guidelines redefined stage 1 hypertension, but its impact on microvascular endothelial dysfunction is unclear.
  • Endothelial dysfunction, particularly nitric oxide (NO)-dependent dilation, is a key factor in hypertension pathogenesis.
  • Assessing endothelial function across hypertension stages is crucial for understanding disease progression.

Purpose of the Study:

  • To determine if cutaneous microvascular endothelial dysfunction is present in stage 1 hypertension (HTN1) compared to normotensive adults (NTN).
  • To compare the severity of endothelial dysfunction in HTN1 and stage 2 hypertension (HTN2).
  • To investigate if impairments in NO-dependent dilation mediate this graded dysfunction.

Main Methods:

  • Retrospective analysis of 20 NTN, 22 HTN1, and 44 HTN2 adults.
  • 24-h ambulatory blood pressure monitoring to assess BP and nocturnal dipping status.
  • Laser Doppler flowmetry during microdialysis with acetylcholine (ACh) and L-NAME to measure NO-dependent dilation.

Main Results:

  • ACh-induced vasodilation was impaired in HTN2 (P < 0.01) but not HTN1 (P = 0.85) compared to NTN.
  • Reductions in NO-dependent dilation were observed in HTN2 (P < 0.01) but not HTN1 (P = 0.76).
  • Endothelium-dependent dilation was impaired in non-dippers, irrespective of hypertension classification (P < 0.05).

Conclusions:

  • Functional impairments in NO-mediated endothelium-dependent dilation are not evident in stage 1 hypertension.
  • Lack of nocturnal blood pressure dipping is associated with blunted endothelium-dependent dilation, regardless of hypertension stage.
  • This study provides the first pharmacological assessment of endothelial function in adults classified by 2017 AHA/ACC hypertension guidelines.

Related Concept Videos

Hypertension I: Introduction01:28

Hypertension I: Introduction

Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
537
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
346
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
577
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
230
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
442
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
203